Putative markers for the detection of early-stage bladder cancer selected by urine metabolomics

Background Early detection of bladder cancer remains challenging because patients with early-stage bladder cancer usually have no incentive to take cytology or cystoscopy tests if they are asymptomatic. Our goal is to find non-invasive marker candidates that may help us gain insight into the metabolism of early-stage bladder cancer and be examined in routine health checks. Results We acquired urine samples from 124 patients diagnosed with early-stage bladder cancer or hernia (63 cancer patients and 61 controls). In which 100 samples were included in our marker discovery cohort, and the remaining 24 samples were included in our independent test cohort. We obtained metabolic profiles of 922 compounds of the samples by gas chromatography-mass spectrometry. Based on the metabolic profiles of the marker discovery cohort, we selected marker candidates using Wilcoxon rank-sum test with Bonferroni correction and leave-one-out cross-validation; we further excluded compounds detected in less than 60% of the bladder cancer samples. We finally selected eight putative markers. The abundance of all the eight markers in bladder cancer samples was high but extremely low in hernia samples. Moreover, the up-regulation of these markers might be in association with sugars and polyols metabolism. Conclusions In the present study, comparative urine metabolomics selected putative metabolite markers for the detection of early-stage bladder cancer. The suggested relations between early-stage bladder cancer and sugars and polyols metabolism may create opportunities for improving the detection of bladder cancer.

[1]  S. Landas,et al.  Oxidative stress, inflammation and carcinogenesis are controlled through the pentose phosphate pathway by transaldolase. , 2011, Trends in molecular medicine.

[2]  Honglin Chen,et al.  GC/MS-based metabolomics reveals fatty acid biosynthesis and cholesterol metabolism in cell lines infected with influenza A virus. , 2010, Talanta.

[3]  F. Freiha.  Staging of bladder cancer. , 1988, Progress in clinical and biological research.

[4]  Robert Powers,et al.  Multivariate Analysis in Metabolomics. , 2012, Current Metabolomics.

[5]  F. Ameye,et al.  Bladder Cancer Diagnosis and Follow-Up: The Current Status and Possible Role of Extracellular Vesicles , 2019, International journal of molecular sciences.

[6]  Eric R. Ziegel,et al.  Generalized Linear Models , 2002, Technometrics.

[7]  N. Keyfitz.  Sampling with Probabilities Proportional to Size: Adjustment for Changes in the Probabilities , 1951 .

[8]  S. Gregory,et al.  Comparison of GC-MS and GC×GC-MS in the analysis of human serum samples for biomarker discovery. , 2015, Journal of proteome research.

[9]  Kishore K. Pasikanti,et al.  Noninvasive urinary metabonomic diagnosis of human bladder cancer. , 2010, Journal of proteome research.

[10]  S. Shapiro,et al.  An Analysis of Variance Test for Normality (Complete Samples) , 1965 .

[11]  J. Kinoshita,et al.  Aldose reductase in diabetic cataracts. , 1981, JAMA.

[12]  A. Criollo,et al.  Aldose Reductase Induced by Hyperosmotic Stress Mediates Cardiomyocyte Apoptosis , 2003, Journal of Biological Chemistry.

[13]  G. Mowatt,et al.  Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. , 2010, Health technology assessment.

[14]  A. Frumkin,et al.  Transaldolase Deficiency: A New Case Expands the Phenotypic Spectrum. , 2016, JIMD reports.

[15]  W. Chung,et al.  Novel association of early onset hepatocellular carcinoma with transaldolase deficiency. , 2014, JIMD reports.

[16]  Jacques Ferlay,et al.  Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. , 2017, European urology.

[17]  K. Ramana,et al.  Targeting aldose reductase for the treatment of cancer. , 2011, Current cancer drug targets.

[18]  V. Tolstikov.  Metabolic analysis. , 2009, Methods in molecular biology.

[19]  C. Roehrborn,et al.  Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. , 2003, Urology.

[20]  Jau-Song Yu,et al.  Mass accuracy improvement of reversed-phase liquid chromatography/electrospray ionization mass spectrometry based urinary metabolomic analysis by post-run calibration using sodium formate cluster ions. , 2014, Rapid communications in mass spectrometry : RCM.

[21]  H. Kitamura,et al.  Early bladder cancer: concept, diagnosis, and management , 2006, International Journal of Clinical Oncology.

[22]  Yingli Lu,et al.  Risk of bladder cancer in patients with diabetes mellitus: an updated meta-analysis of 36 observational studies , 2013, BMC Cancer.

[23]  Jeffrey Gahan,et al.  Photodynamic diagnosis in urology: state of the art. , 2011, Archivos espanoles de urologia.

[24]  W. Miekisch,et al.  Deficiency and absence of endogenous isoprene in adults, disqualified its putative origin , 2021, Heliyon.

[25]  T. Takenawa,et al.  A Novel Serum Metabolomics-Based Diagnostic Approach to Pancreatic Cancer , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[26]  Kishore K. Pasikanti,et al.  Gas chromatography/mass spectrometry in metabolic profiling of biological fluids. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[27]  I. Bertini,et al.  Metabolomics: available results, current research projects in breast cancer, and future applications. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Ruiz-Argüello,et al.  A New Biomarker Panel in Bronchoalveolar Lavage for an Improved Lung Cancer Diagnosis , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  F. Wilcoxon.  Individual Comparisons by Ranking Methods , 1945 .

[30]  R. Nelson,et al.  Comparison of GC–MS, GC–MRM-MS, and GC × GC to characterise higher plant biomarkers in Tertiary oils and rock extracts , 2012 .

[31]  W. Chung,et al.  Mutations in TKT Are the Cause of a Syndrome Including Short Stature, Developmental Delay, and Congenital Heart Defects. , 2016, American journal of human genetics.

[32]  Dieter Jocham,et al.  Photodynamic diagnosis in urology: state-of-the-art. , 2008, European urology.

[33]  Y. Lotan,et al.  Bladder Cancer Biomarker Discovery Using Global Metabolomic Profiling of Urine , 2014, PloS one.

[34]  A. Lopez‐Beltran,et al.  Staging of bladder cancer , 2018, Histopathology.

[35]  M. S. van der Knaap,et al.  Ribose-5-phosphate isomerase deficiency: new inborn error in the pentose phosphate pathway associated with a slowly progressive leukoencephalopathy. , 2004, American journal of human genetics.

[36]  Paul C Ho,et al.  Urinary metabotyping of bladder cancer using two-dimensional gas chromatography time-of-flight mass spectrometry. , 2013, Journal of proteome research.

[37]  Maxim N. Artyomov,et al.  The microbial metabolite desaminotyrosine protects from influenza through type I interferon , 2017, Science.

[38]  R. Oelmüller,et al.  Metabolomic compounds identified in Piriformospora indica-colonized Chinese cabbage roots delineate symbiotic functions of the interaction , 2017, Scientific Reports.

[39]  P. McCullagh,et al.  Generalized Linear Models , 1972, Predictive Analytics.

[40]  B. Têtu,et al.  Diagnosis of urothelial carcinoma from urine , 2009, Modern Pathology.

[41]  N. Hay,et al.  The pentose phosphate pathway and cancer. , 2014, Trends in biochemical sciences.

[42]  F. Middleton,et al.  Prevention of hepatocarcinogenesis and increased susceptibility to acetaminophen-induced liver failure in transaldolase-deficient mice by N-acetylcysteine. , 2009, The Journal of clinical investigation.

[43]  B. Kessler,et al.  Optimizing 2D gas chromatography mass spectrometry for robust tissue, serum and urine metabolite profiling , 2017, Talanta.

[44]  P. Chang,et al.  Comparative and targeted proteomic analyses of urinary microparticles from bladder cancer and hernia patients. , 2012, Journal of proteome research.

[45]  M. Knaap,et al.  Transaldolase deficiency: liver cirrhosis associated with a new inborn error in the pentose phosphate pathway. , 2001, American journal of human genetics.

[46]  Qi Zhang,et al.  GC/MS analysis of the rat urine for metabonomic research. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[47]  E. Fukusaki,et al.  A metabolomic approach to lung cancer. , 2011, Lung cancer.

[48]  S. Larsson,et al.  Diabetes mellitus and risk of bladder cancer: a meta-analysis , 2006, Diabetologia.